STAAR Surgical (NASDAQ: STAA) Receives Average “Keep” Analyst Rating



Shares of STAAR Surgical (NASDAQ: STAA) received an average rating of “Hold” from the six rating companies that currently hedge the stock, reports. Four equity research analysts rated the stock with a conservation rating and one issued a buy rating on the company. The 12-month average target price among analysts who updated their stock coverage in the past year is $ 150.00.

Several research analysts have published reports on the company. Zacks investment research downgraded STAAR Surgical from a “buy” rating to a “conservation” rating in a research note on Wednesday, November 3. TheStreet downgraded STAAR Surgical from a “b” rating to a “c +” rating in a report released on Tuesday, September 28th.

In addition, CEO Caren L. Mason sold 35,000 shares in a transaction that took place on Thursday, November 18. The stock was sold for an average price of $ 113.83, for a total value of $ 3,984,050.00. The sale was disclosed in a file with the Securities & Exchange Commission, accessible via the SEC website. Additionally, CTO Keith Holliday sold 6,000 shares in a trade that took place on Tuesday, December 14th. The stock was sold for an average price of $ 89.57, for a total value of $ 537,420.00. Disclosure of this sale can be found here. Insiders sold a total of 76,000 shares of the company valued at $ 8,518,470 during the last quarter. Company insiders own 3.60% of the company’s shares.

Hedge funds and other institutional investors have recently changed their positions in the company. Russell Investments Group Ltd. increased its stake in STAAR Surgical by 292.7% during the second quarter. Russell Investments Group Ltd. now owns 52,694 shares of the medical device supplier valued at $ 8,033,000 after purchasing an additional 39,274 shares during the period. Envestnet Asset Management Inc. increased its position in STAAR Surgical by 76.0% during the second quarter. Envestnet Asset Management Inc. now owns 24,063 shares of the medical device supplier valued at $ 3,670,000 after purchasing an additional 10,387 shares in the last quarter. Teacher Retirement System of Texas increased its position in STAAR Surgical by 17.8% during the second quarter. Teacher Retirement System of Texas now owns 4,466 shares of the medical device supplier valued at $ 681,000 after purchasing an additional 676 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in STAAR Surgical shares in the second quarter valued at approximately $ 904,000. Finally, the Swiss National Bank increased its holdings in STAAR Surgical shares by 3.9% in the second quarter. The Swiss National Bank now owns 82,100 shares of the medical device supplier valued at $ 12,520,000 after purchasing an additional 3,100 shares during the period. 87.66% of the shares are held by institutional investors and hedge funds.

Actions of STAAR surgical stock open for $ 91.30 on Mondays. The company’s 50-day mobile average price is $ 103.18, and its two-hundred-day mobile average price is $ 125.62. The stock has a market cap of $ 4.35 billion, a PE ratio of 198.48 and a beta of 0.95. STAAR Surgical has a 52 week low of $ 77.74 and a 52 week high of $ 163.08.

STAAR Surgical (NASDAQ: STAA) last released its results on Wednesday, November 3. The medical device supplier reported earnings per share of $ 0.12 for the quarter, beating consensus analysts’ estimates of $ 0.11 by $ 0.01. The company posted revenue of $ 58.35 million for the quarter, compared to a consensus estimate of $ 57.70 million. STAAR Surgical recorded a return on equity of 13.06% and a net margin of 10.53%. In the same quarter of the previous year, the company achieved EPS of $ 0.14. Equity research analysts predict that STAAR Surgical will post EPS of 0.55 for the current fiscal year.

STAAR Surgical Company Profile

STAAR Surgical Co is engaged in the development, manufacture, production, marketing and sale of implantable eye lenses and delivery systems used to introduce lenses into the eye. She specializes in refraction and cataract solutions. Its products include an intraocular lens and an implantable collapsible lens.

Read more: What is the formula for the cash asset ratio?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in STAAR Surgical now?

Before you consider STAAR Surgical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and STAAR Surgical was not on the list.

While STAAR Surgical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here



About Author

Comments are closed.